Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5546769 | 0.90 | TSHR (0.51) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL5535046 | 0.88 | TSHR (0.50) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL67263 | 0.87 | TSHR (0.49) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL5542243 | 0.87 | KCNH2 (0.49) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL5535033 | 0.87 | KCNH2 (0.49) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL7757641 | 0.84 | TSHR (0.53) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL7083059 | 0.84 | TSHR (0.53) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL7758234 | 0.84 | TSHR (0.53) | TSHRKCNH2IDO1KCNJ1LOXL2 | |
| SCHEMBL1212 | 0.81 | IDO1 (0.61) | TSHRIDO1LOXL2AKR1C3CHRM2 | |
| SCHEMBL3656180 | 0.81 | TSHR (0.62) | TSHRKCNH2IDO1KCNJ1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 640 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584956-B2 | Selectively controllable cleavable linkers | MICROSOFT TECHNOLOGY LICENSING, LLC (US) | 2023-02-21 | — | — | US | claimed |
| EP-2921499-B1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-22 | — | — | EP | claimed |
| EP-2567964-B1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES INC (US) | 2015-02-11 | — | — | EP | claimed |
| EP-2567964-A2 | Monomer Compositions for the Synthesis of RNA, Methods of Synthesis, and Methods of Deprotection | Agilent Technologies, Inc. (US) | 2013-03-13 | — | — | EP | claimed |
| US-7759471-B2 | nucleotide monomer used to make protected RNA that has similar stability to the DNA molecule | AGILENT TECHNOLOGIES, INC. (US) | 2010-07-20 | — | — | US | claimed |
| US-7759513-B2 | Photolabile protective groups for improved processes to prepare oligonucleotide arrays | NIGU CHEMIE GMBH (DE) | 2010-07-20 | — | — | US | claimed |
| EP-1379698-B1 | MOBILITY-MODIFIED NUCLEOBASE POLYMERS AND METHODS OF USING SAME | APPLIED BIOSYSTEMS LLC (US) | 2009-08-26 | — | — | EP | claimed |
| EP-2001896-A2 | MONOMER COMPOSITIONS FOR THE SYNTHESIS OF RNA, METHODS OF SYNTHESIS, AND METHODS OF DEPROTECTION | Agilent Technologies, Inc. (US) | 2008-12-17 | — | — | EP | claimed |
| WO-2007112263-A2 | MONOMER COMPOSITIONS FOR THE SYNTHESIS OF RNA, METHODS OF SYNTHESIS, AND METHODS OF DEPROTECTION | AGILENT TECHNOLOGIES, INC. (US) | 2007-10-04 | — | — | WO | claimed |
| US-20070100136-A1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES, INC. | 2007-05-03 | — | — | US | claimed |
| US-5756695-A | MONOSIALOGANGLISIDE | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 1998-05-26 | — | — | US | claimed |
| EP-0821691-A1 | METHODS OF SYNTHESIZING GM2 | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 1998-02-04 | — | — | EP | claimed |
| WO-1997041139-A2 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KOESTER HUBERT (US) | 1997-11-06 | — | — | WO | claimed |
| WO-1997030061-A1 | METHODS OF SYNTHESIZING GM2 | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 1997-08-21 | — | — | WO | claimed |
| US-5652358-A | Solid-phase synthesis of oligoribonucleotides | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-07-29 | — | — | US | claimed |
| EP-0759927-A1 | PTERIDINE NUCLEOTIDE ANALOGS AS FLUORESCENT DNA PROBES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-03-05 | — | — | EP | claimed |
| US-5525711-A | MONOMERS FOR DNA AMPLIFICATION PROCEDURES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-06-11 | — | — | US | claimed |
| WO-1995031469-A1 | PTERIDINE NUCLEOTIDE ANALOGS AS FLUORESCENT DNA PROBES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-11-23 | — | — | WO | claimed |
| EP-0648220-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA, Jyoti (SE) | 1995-04-19 | — | — | EP | claimed |
| WO-1993025566-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA JYOTI (SE) | 1993-12-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100136-A1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | RNGTT, RNMT, NSUN2 | TSHR 4260/4885KCNH2 4669/4885IDO1 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.